• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

异基因造血细胞移植环境中的树突状细胞疗法：实现更好疾病控制的有效策略？

Dendritic Cell Therapy in an Allogeneic-Hematopoietic Cell Transplantation Setting: An Effective Strategy toward Better Disease Control?

作者信息

Plantinga Maud, de Haar Colin, Nierkens Stefan, Boelens Jaap Jan

机构信息

Utrecht - Dendritic cells AgaiNst CancEr (U-DANCE), Laboratory of Translational Immunology, Department of Immunology, University Medical Centre Utrecht , Utrecht , Netherlands.

Utrecht - Dendritic cells AgaiNst CancEr (U-DANCE), Laboratory of Translational Immunology, Department of Immunology, University Medical Centre Utrecht , Utrecht , Netherlands ; Pediatric Blood and Marrow Transplantation Program, Department of Immunology, University Medical Centre Utrecht , Utrecht , Netherlands.

出版信息

Front Immunol. 2014 May 19;5:218. doi: 10.3389/fimmu.2014.00218. eCollection 2014.

DOI:10.3389/fimmu.2014.00218
PMID:24904573
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4032952/
Abstract

Hematopoietic cell transplantation (HCT) is a last treatment resort and only potentially curative treatment option for several hematological malignancies resistant to chemotherapy. The induction of profound immune regulation after allogeneic HCT is imperative to prevent graft-versus-host reactions and, at the same time, allow protective immune responses against pathogens and against tumor cells. Dendritic cells (DCs) are highly specialized antigen-presenting cells that are essential in regulating this balance and are of major interest as a tool to modulate immune responses in the complex and challenging phase of immune reconstitution early after allo-HCT. This review focuses on the use of DC vaccination to prevent cancer relapses early after allo-HCT. It describes the role of host and donor-DCs, various vaccination strategies, different DC subsets, antigen loading, DC maturation/activation, and injection sites and dose. At last, clinical trials using DC vaccination post-allo-HCT and the future perspectives of DC vaccination in combination with other cancer immunotherapies are discussed.

摘要

造血细胞移植（HCT）是一种最后的治疗手段，也是几种对化疗耐药的血液系统恶性肿瘤唯一可能的治愈性治疗选择。异基因造血细胞移植后诱导深度免疫调节对于预防移植物抗宿主反应至关重要，同时还能允许针对病原体和肿瘤细胞产生保护性免疫反应。树突状细胞（DCs）是高度专业化的抗原呈递细胞，对于调节这种平衡至关重要，并且作为一种在异基因造血细胞移植后早期复杂且具有挑战性的免疫重建阶段调节免疫反应的工具备受关注。本综述聚焦于使用树突状细胞疫苗接种预防异基因造血细胞移植后早期癌症复发。它描述了宿主和供体树突状细胞的作用、各种疫苗接种策略、不同的树突状细胞亚群、抗原负载、树突状细胞成熟/激活以及注射部位和剂量。最后，讨论了异基因造血细胞移植后使用树突状细胞疫苗接种的临床试验以及树突状细胞疫苗接种与其他癌症免疫疗法联合应用的未来前景。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8670/4032952/82ca0c60fd89/fimmu-05-00218-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8670/4032952/1ca3ac01127e/fimmu-05-00218-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8670/4032952/82ca0c60fd89/fimmu-05-00218-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8670/4032952/1ca3ac01127e/fimmu-05-00218-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8670/4032952/82ca0c60fd89/fimmu-05-00218-g002.jpg

相似文献

1
Dendritic Cell Therapy in an Allogeneic-Hematopoietic Cell Transplantation Setting: An Effective Strategy toward Better Disease Control?异基因造血细胞移植环境中的树突状细胞疗法：实现更好疾病控制的有效策略？
Front Immunol. 2014 May 19;5:218. doi: 10.3389/fimmu.2014.00218. eCollection 2014.
2
Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.异基因反应性作为血液系统恶性肿瘤治疗的治疗原则。非清髓性预处理的异基因造血细胞移植的临床和免疫学方面的研究。
Dan Med Bull. 2007 May;54(2):112-39.
3
Ikaros deficiency in host hematopoietic cells separates GVL from GVHD after experimental allogeneic hematopoietic cell transplantation.实验性异基因造血细胞移植后，宿主造血细胞中Ikaros缺乏可将移植物抗白血病效应与移植物抗宿主病区分开来。
Oncoimmunology. 2015 Apr 1;4(7):e1016699. doi: 10.1080/2162402X.2015.1016699. eCollection 2015 Jul.
4
Immune Reconstitution after Allogeneic Hematopoietic Cell Transplantation in Children.儿童异基因造血细胞移植后的免疫重建
Biol Blood Marrow Transplant. 2016 Feb;22(2):195-206. doi: 10.1016/j.bbmt.2015.08.028. Epub 2015 Sep 1.
5
Host-derived CD8+ dendritic cells are required for induction of optimal graft-versus-tumor responses after experimental allogeneic bone marrow transplantation.宿主来源的 CD8+ 树突状细胞是实验性异基因骨髓移植后诱导最佳移植物抗肿瘤反应所必需的。
Blood. 2013 May 16;121(20):4231-41. doi: 10.1182/blood-2012-05-432872. Epub 2013 Mar 21.
6
Effect of Sirolimus on Immune Reconstitution Following Myeloablative Allogeneic Stem Cell Transplantation: An Ancillary Analysis of a Randomized Controlled Trial Comparing Tacrolimus/Sirolimus and Tacrolimus/Methotrexate (Blood and Marrow Transplant Clinical Trials Network/BMT CTN 0402).西罗莫司对骨髓清除性异基因造血干细胞移植后免疫重建的影响：一项比较他克莫司/西罗莫司与他克莫司/甲氨蝶呤的随机对照试验的辅助分析（血液和骨髓移植临床试验网络/BMT CTN 0402）。
Biol Blood Marrow Transplant. 2019 Nov;25(11):2143-2151. doi: 10.1016/j.bbmt.2019.06.029. Epub 2019 Jul 2.
7
Hematopoietic stem cell-derived myeloid and plasmacytoid DC-based vaccines are highly potent inducers of tumor-reactive T cell and NK cell responses .造血干细胞来源的髓样和浆细胞样树突状细胞疫苗是肿瘤反应性T细胞和NK细胞反应的高效诱导剂。
Oncoimmunology. 2017 Feb 6;6(3):e1285991. doi: 10.1080/2162402X.2017.1285991. eCollection 2017.
8
Rapid establishment of dendritic cell chimerism in allogeneic hematopoietic cell transplant recipients.异基因造血细胞移植受者中树突状细胞嵌合状态的快速建立
Blood. 2002 Feb 15;99(4):1442-8. doi: 10.1182/blood.v99.4.1442.
9
Can tolerogenic dendritic cells help to modulate allo-immune responses in the setting of hematopoietic cell transplantation?耐受性树突状细胞能否有助于调节造血细胞移植中的同种免疫反应？
Transpl Immunol. 2003 Jul-Sep;11(3-4):259-66. doi: 10.1016/S0966-3274(03)00053-4.
10
Extracellular Vesicles After Allogeneic Hematopoietic Cell Transplantation: Emerging Role in Post-Transplant Complications.异基因造血细胞移植后细胞外囊泡：在后移植并发症中的新兴作用。
Front Immunol. 2020 Mar 20;11:422. doi: 10.3389/fimmu.2020.00422. eCollection 2020.

引用本文的文献

1
Relevance of immune cell and tumor microenvironment imaging in the new era of immunotherapy.免疫细胞和肿瘤微环境成像在免疫治疗新时代的相关性。
J Exp Clin Cancer Res. 2020 May 18;39(1):89. doi: 10.1186/s13046-020-01586-y.
2
Strategies to Genetically Modulate Dendritic Cells to Potentiate Anti-Tumor Responses in Hematologic Malignancies.策略性基因修饰树突状细胞以增强血液恶性肿瘤的抗肿瘤反应。
Front Immunol. 2018 May 18;9:982. doi: 10.3389/fimmu.2018.00982. eCollection 2018.
3
Hitting the Holy Grail of Hematopoietic Cell Transplantation with Naive T-Cell Depleted Allografts-Graft Engineered Hematopoietic Stem Cell Transplant.

本文引用的文献

1
Dendritic cells and cancer immunotherapy.树突状细胞与癌症免疫疗法。
Curr Opin Immunol. 2014 Apr;27:26-32. doi: 10.1016/j.coi.2014.01.005. Epub 2014 Feb 8.
2
Antitumor immune responses mediated by dendritic cells: How signals derived from dying cancer cells drive antigen cross-presentation.树突状细胞介导的抗肿瘤免疫反应：源自死亡癌细胞的信号如何驱动抗原交叉呈递。
Oncoimmunology. 2013 Nov 1;2(11):e26403. doi: 10.4161/onci.26403. Epub 2013 Oct 21.
3
The aryl hydrocarbon receptor antagonist StemRegenin 1 promotes human plasmacytoid and myeloid dendritic cell development from CD34+ hematopoietic progenitor cells.
利用去除幼稚T细胞的同种异体移植物实现造血细胞移植的圣杯——移植物工程化造血干细胞移植。
Biomedicines. 2017 Aug 14;5(3):48. doi: 10.3390/biomedicines5030048.
4
Targeting of the WT1 fragment to human dendritic cells improves leukemia-specific T-cell responses providing an alternative approach to WT1-based vaccination.将WT1片段靶向人树突状细胞可改善白血病特异性T细胞反应，为基于WT1的疫苗接种提供了一种替代方法。
Cancer Immunol Immunother. 2017 Mar;66(3):319-332. doi: 10.1007/s00262-016-1938-y. Epub 2016 Nov 28.
5
Progress in Treatment of Viral Infections in Children with Acute Lymphoblastic Leukemia.儿童急性淋巴细胞白血病病毒感染的治疗进展
Oncol Rev. 2016 Jun 30;10(1):300. doi: 10.4081/oncol.2016.300. eCollection 2016 Apr 15.
6
Current status and perspectives of immune-based therapies for hepatocellular carcinoma.肝细胞癌免疫治疗的现状与展望
World J Gastroenterol. 2016 Jan 7;22(1):253-61. doi: 10.3748/wjg.v22.i1.253.
7
Application of antigen cross-presentation research into patient care.抗原交叉呈递研究在患者护理中的应用。
Front Immunol. 2014 Jun 17;5:287. doi: 10.3389/fimmu.2014.00287. eCollection 2014.
芳烃受体拮抗剂StemRegenin 1可促进人浆细胞样和髓样树突状细胞从CD34+造血祖细胞发育而来。
Stem Cells Dev. 2014 May 1;23(9):955-67. doi: 10.1089/scd.2013.0521. Epub 2014 Jan 24.
4
Origin of Langerhans cells in normal skin and chronic GVHD after hematopoietic stem-cell transplantation.造血干细胞移植后正常皮肤和慢性移植物抗宿主病中朗格汉斯细胞的起源。
Exp Dermatol. 2014 Jan;23(1):75-7. doi: 10.1111/exd.12301.
5
Harnessing dendritic cells for tumor antigen presentation.利用树突状细胞进行肿瘤抗原呈递。
Cancers (Basel). 2011 Apr 26;3(2):2195-213. doi: 10.3390/cancers3022195.
6
Impact of thymoglobulin prior to pediatric unrelated umbilical cord blood transplantation on immune reconstitution and clinical outcome.胸腺球蛋白对小儿非亲缘脐带血移植后免疫重建和临床结局的影响。
Blood. 2014 Jan 2;123(1):126-32. doi: 10.1182/blood-2013-05-502385. Epub 2013 Nov 1.
7
Prevention of graft-versus-host-disease with preserved graft-versus-leukemia-effect by ex vivo and in vivo modulation of CD4(+) T-cells.通过体外和体内调节 CD4(+)T 细胞预防移植物抗宿主病保留移植物抗白血病效应。
Cell Mol Life Sci. 2014 Jun;71(11):2135-48. doi: 10.1007/s00018-013-1476-0. Epub 2013 Sep 26.
8
Adoptive T cell transfer for cancer immunotherapy in the era of synthetic biology.采用合成生物学进行癌症免疫疗法中的过继细胞转移。
Immunity. 2013 Jul 25;39(1):49-60. doi: 10.1016/j.immuni.2013.07.002.
9
Oncology meets immunology: the cancer-immunity cycle.肿瘤学与免疫学：癌症免疫周期。
Immunity. 2013 Jul 25;39(1):1-10. doi: 10.1016/j.immuni.2013.07.012.
10
Challenges and opportunities for international cooperative studies in pediatric hematopoeitic cell transplantation: priorities of the Westhafen Intercontinental Group.儿科造血细胞移植国际合作研究的挑战与机遇：威斯特法伦洲际组的优先事项。
Biol Blood Marrow Transplant. 2013 Sep;19(9):1279-87. doi: 10.1016/j.bbmt.2013.07.006. Epub 2013 Jul 21.